Woolley ML, Marsden CA, Fone KC. 5-ht6 receptors. Curr Drug Targets CNS Neurol Disord 2004;3:59–79.
Monsma Jr FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993;43:320–7.
Ruat M, Traiffort E, Arrang JM, Tardivel-Lacombe J, Diaz J, Leurs R, et al. A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochem Biophys Res Commun 1993;193:268–76.
Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, et al. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem 1996;66:47–56.
Glennon RA. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem 2003;46:2795–812.
Boess FG, Riemer C, Bös M, Bentley J, Bourson A, Sleight AJ. The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63–0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum. Mol Pharmacol 1998;54:577–83.
East SZ, Burnet PW, Leslie RA, Roberts JC, Harrison PJ. 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. Synapse 2002;45:191–9.
Hirst WD, Minton JA, Bromidge SM, Moss SF, Latter AJ, Riley G, et al. Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue. Br J Pharmacol 2000;130:1597–605.
Roberts JC, Reavill C, East SZ, Harrison PJ, Patel S, Routledge C, et al. The distribution of 5-HT(6) receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]SB-258585. Brain Res 2002;934:49–57.
Dawson LA. The central role of 5-HT6 receptors in modulating brain neurochemistry. Int Rev Neurobiol 2011;96:1–26.
Arnt J, Olsen CK. 5-HT6 receptor ligands and their antipsychotic potential. Int Rev Neurobiol 2011;96:141–61.
Mitchell ES. 5-HT6 receptor ligands as antidementia drugs. Int Rev Neurobiol 2011;96:163–87.
Quiedeville A, Boulouard M, Da Silva Costa-Aze V, Dauphin F, Bouet V, Freret T. 5-HT6 receptor antagonists as treatment for age-related cognitive decline. Rev Neurosci 2014;25:417–27.
Heal D, Gosden J, Smith S. The 5-HT6 receptor as a target for developing novel antiobesity drugs. Int Rev Neurobiol 2011;96:73–109.
Lancelot S, Zimmer L. Small-animal positron emission tomography as a tool for neuropharmacology. Trends Pharmacol Sci 2010;31:411–7.
Zimmer L, Luxen A. PET radiotracers for molecular imaging in the brain: past, present and future. Neuroimage 2012;61:363–70.
Lee CM, Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 2006;27:310–6.
Branchek TA, Blackburn TP. 5-ht6 receptors as emerging targets for drug discovery. Annu Rev Pharmacol Toxicol 2000;40:319–34.
Tang S, Verdurand M, Joseph B, Lemoine L, Daoust A, Billard T, et al. Synthesis and biological evaluation in rat and cat of [18F]12ST05 as a potential 5-HT6 PET radioligand. Nucl Med Biol 2007;34:995–1002.
Ahmed M, Jones MC, MacDonald GJ, Moss SF, Thompson M, Wade CE, Witty D. Preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders. Patent Application Publication WO2003080580A2 2003.
Martarello L, Ahmed M, Chuang AT, Cunnigham VJ, Jakobsen S, Johnson CN, et al. Radiolabelling and in vivo evaluation of [11C]GSK210583 as a potential 5-HT6 PET radioligand in the porcine brain. J Labelled Comp Radiopharm 2005;48:341.
Comley RA, Salinas C, Mizrahi R, Vitcu I, Ng A, Hallett W, et al. Biodistribution and radiation dosimetry of the serotonin 5-HT(6) ligand [11C]GSK215083 determined from human whole-body PET. Mol Imaging Biol 2012;14:517–21.
Parker CA, Gunn RN, Rabiner EA, Slifstein M, Comley R, Salinas C, et al. Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor. J Nucl Med 2012;53:295–303.
Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain--IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987;21:123–39.
Liu F, Majo VJ, Prabhakaran J, Milak MS, John Mann J, Parsey RV, et al. Synthesis and in vivo evaluation of [O-methyl-11C] N-[3,5-dichloro-2-(methoxy)phenyl]-4-(methoxy)-3-(1-piperazinyl)benzenesulfonamide as an imaging probe for 5-HT6 receptors. Bioorg Med Chem 2011;19:5255–9.
Zhang LV A, Anderson D, Beck E, Blumberg L, Bocan T, Bronk B, et al. Development of design and selection parameters to accelerate the discovery process of novel CNS PET ligands and their application in the identification of a potential 5HT6 PET ligand [11C]PF-1. J Labelled Comp Radiopharm 2011;54:S292.
Black LA. Radiolabeled 5-HT6 ligands. Patent Application Publication US 2013/0343993A1.
Colomb J, Becker G, Fieux S, Zimmer L, Billard T. Syntheses, radiolabelings, and in vitro evaluations of fluorinated PET radioligands of 5-HT6 serotoninergic receptors. J Med Chem 2014;57:3884–90.
Snyder WT. A stereotaxic atlas of the cat brain. Chicago: University of Chicago Press; 1961.
Ballanger B, Tremblay L, Sgambato-Faure V, Beaudoin-Gobert M, Lavenne F, Le Bars D, et al. A multi-atlas based method for automated anatomical Macaca fascicularis brain MRI segmentation and PET kinetic extraction. Neuroimage 2013;77:26–43.
Gérard C, Martres MP, Lefèvre K, Miquel MC, Vergé D, Lanfumey L, et al. Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res 1997;746:207–19.
Mitchell ES, Neumaier JF. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol Ther 2005;108:320–33.
Fagerholm U. The highly permeable blood-brain barrier: an evaluation of current opinions about brain uptake capacity. Drug Discov Today 2007;12:1076–82.
Waterhouse RN. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 2003;5:376–89.
Elsinga PH, Hendrikse NH, Bart J, Vaalburg W, van Waarde A. PET studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des 2004;10:1493–503.
Laćan G, Plenevaux A, Rubins DJ, Way BM, Defraiteur C, Lemaire C, et al. Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies. Eur J Nucl Med Mol Imaging 2008;35:2256–66.
Hirst WD, Abrahamsen B, Blaney FE, Calver AR, Aloj L, Price GW, et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol 2003;64:1295–308.
